Navigation Links
Valensa Completes Second Expansion of Astaxanthin Capacity
Date:4/14/2009

"Made in USA" label and allergen-free status of extracted product driving demand

ORLANDO, Fla., April 14 /PRNewswire/ -- Valensa International announced that it has completed a second round of expansion for astaxanthin production at its Eustis, Florida facility. The move was made in light of growing demand for a high-quality astaxanthin from North America that is both pesticide-free and allergen-free -- two conditions that are only possible with carefully controlled raw material monitoring and extraction facilities that are not used for extractions of materials that are known to cause allergic reactions, such as legumes and shellfish. The company announced a 20% expansion of capacity in February 2008. With the new capacity, Valensa is now producing 40% more of its ZANTHIN(R) natural astaxanthin extract than it did in 2007.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the recent expansions have come as a result of rapidly increasing demand in Europe for astaxanthin for eye health formulations, but have also been fueled by European and U.S.-based companies needing to establish a clear country of origin for their astaxanthin products as well as assuage concerns about potential contamination by allergenic materials. "Right now, Valensa International is the only company in the market who manufactures -- or extracts -- astaxanthin oleoresin in the United States. As a fully integrated supplier of astaxanthin, our customers can rely on where their product gets made," Moerck said. "When marketers of natural astaxanthin contract out for the extraction of biomass to produce natural astaxanthin, there is a chance that the extracting company will process multiple raw materials through the same facilities. We have seen instances in the market where materials such as shellfish are produced in the same facilities as astaxanthin and are sold without appropriate label warnings introducing the possibility of allergenicity into the final astaxanthin extract. Companies who work with Valensa are assured that cross-contamination of this type does not exist, and as a result, have chosen a fully integrated solution from sourcing algae biomass, to CO2 extraction and standardization," he added.

Made in the USA

Valensa's ZANTHIN(R) natural astaxanthin is an ultra-high pressure supercritical CO2 extraction of Haematococcus pluvialis freshwater algae that uses no chemical solvents. Valensa is the only fully integrated supplier of natural astaxanthin extract in the U.S. It is made to cGMP standards in a certified organic facility in Florida and the product is protected with Valensa's all-natural, proprietary O2B(R) stabilization technology which provides extra stability in storage, efficacy and in customer's formulations. Valensa's approach to manufacturing ensures the highest-quality, most consistent product on the market -- and recommends it for eye health and for its potent anti-oxidant properties.

"Quality is critical to the acceptance of astaxanthin in all product formulations especially eye health formulas. At Valensa, we are committed to providing the highest-quality astaxanthin on the market," said Moerck.

    For further information, contact:

    Dr. Rudi Moerck, President and CEO
    Voice: 352-357-2004 ext. 701
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
2. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
3. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
4. Pacer Health Corporation Successfully Completes Assignment of $11.7 Million in Convertible Debentures
5. Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecoms Network Solutions
6. Aegis Living Completes Purchase of Real Estate in Aptos
7. AMICAS Successfully Completes Tender Offer for Shares of Emageon Inc.
8. DST Systems, Inc. Completes Acquisition of Remaining 50% of Argus Health Systems, Inc.
9. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Immunotech Completes Merger Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: